Janssen gets FDA approval for new Darzalex combination

The US Food and Drug Administration has approved yet another combination treatment for bone marrow cancer involving Darzalex – this time, in combination with two other drugs.

Darzalex Faspro has been approved by the FDA in combination with pomalidomide and dexamethasone.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading